Eli Lilly

Company LLY

Last mentioned: 12h ago

Timeline

  1. HIMS Launches GLP-1s

    Hims & Hers enters the weight-loss market with compounded GLP-1 offerings.

  2. Settlement Reached

    Hims & Hers agrees to stop selling compounded GLP-1s to resolve legal disputes.

  3. FDA Shortage Updates

    FDA begins removing specific GLP-1 dosages from the national shortage list.

  4. Litigation Surge

    Novo Nordisk and Eli Lilly file multiple lawsuits against compounding pharmacies and telehealth firms.

Stories mentioning Eli Lilly 1

Regulation Bearish

Hims & Hers Health to Halt Compounded GLP-1 Sales in Landmark Settlement

Hims & Hers Health has agreed to cease the sale of compounded GLP-1 medications as part of a legal settlement, marking a significant shift in the telehealth landscape. This move follows intense regulatory scrutiny and litigation regarding the legality of compounding patented weight-loss drugs during supply shortages.

2 sources